References
L. Pérusse, T. Rankinen, A. Zuberi et al., The human obesity gene map: the 2004 update. Obes. Res. 13, 381–490 (2005)
P. Sumithran, L.A. Prendergast, E. Delbridge, Long-term persistence of hormonal adaptations to weight loss. N. Engl. J. Med. 365, 1597–1604 (2012)
J. Vendrell, M. Broch, N. Vilarrasa et al., Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity. Obes. Res. 12, 962–971 (2004)
E.M. Mathus-Vliegen, Obesity: intragastric balloons—a bubble to combat the obesity bubble? Nat. Rev. Gastroenterol. Hepatol. 7, 7–8 (2010)
M. Nikolic, M. Boban, N. Ljubicic et al., Morbidly obese are ghrelin and leptin hyporesponders with lesser intragastric balloon treatment efficiency: ghrelin and leptin changes in relation to obesity treatment. Obes. Surg. 21, 1597–1604 (2011)
C. Franco, J. Brandberg, L. Lönn et al., Growth hormone treatment reduces abdominal visceral fat in postmenopausal women with abdominal obesity: a 12-month placebo-controlled trial. J. Clin. Endocrinol. Metab. 90, 1466–1474 (2005)
R.M. Luque, R.D. Kineman, Impact of obesity on the growth hormone axis: evidence for a direct inhibitory effect of hyperinsulinemia on pituitary function. Endocrinology 147, 2754–2763 (2006)
V. Mohamed-Ali, J.H. Pinkney, S.W. Coppack, Adipose tissue as an endocrine and paracrine organ. Int. J. Obes. Relat. Metab. Disord. 22, 1145–1158 (1998)
L. De Marinis, A. Bianchi, A. Mancini et al., Growth hormone secretion and leptin in morbid obesity before and after biliopancreatic diversion: relationships with insulin and body composition. J. Clin. Endocrinol. Metab. 89, 174–180 (2004)
J. Gagnon, Y. Anini, Insulin and norepinephrine regulate ghrelin secretion from a rat primary stomach cell culture. Endocrinology 153, 3646–3656 (2012)
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mirošević, G., Nikolić, M., Kruljac, I. et al. Decrease in insulin resistance has a key role in improvement of metabolic profile during intragastric balloon treatment. Endocrine 45, 331–334 (2014). https://doi.org/10.1007/s12020-013-0069-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-013-0069-x